McMurray, John J.V.
University of Glasgow
142 papers on CoChatORCID 0000-0002-6317-3975
Most cited papers
- Verified · note
Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
Swedberg, K., Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J., & Pitt, B. (2012) · Journal of the American College of Cardiology
Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management
Cited by 313
- Verified
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 307
- Verified
Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction
Hung, C.-L., Verma, A., Uno, H., Shin, S.-H., Bourgoun, M., Hassanein, A. H., McMurray, J. J., Velazquez, E. J., Kober, L., Pfeffer, M. A., et al. (2010) · Journal of the American College of Cardiology
Cardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics
Cited by 305
- Verified
Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study)
Murphy, N. F., MacIntyre, K., Stewart, S., Hart, C. L., Hole, D., & McMurray, J. J. V. (2006) · European Heart Journal
Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 298
- Verified
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal
Heart Failure Treatment and ManagementCardiac electrophysiology and arrhythmias
Cited by 256
- Verified
Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus
McAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 244
- Verified
Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017) · Circulation Heart Failure
Heart Failure Treatment and ManagementHeart rate and cardiovascular health
Cited by 238
- Verified
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
Yates, T., Haffner, S. M., Schulte, P. J., Thomas, L., Huffman, K. M., Bales, C. W., Califf, R. M., Holman, R. R., McMurray, J. J. V., Bethel, M. A., et al. (2014) · The Lancet
Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 238
- Verified
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 234
- Verified
N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation
Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., et al. (2013) · Journal of the American College of Cardiology
Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management
Cited by 231
- Verified
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure
Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials
Cited by 231
- Verified
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 227
- Verified
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., & Yusuf, S. (2014) · European Journal of Heart Failure
Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials
Cited by 226
- Verified · note
Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations
Rogers, J. K., McMurray, J. J. V., Pocock, S. J., Zannad, F., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2012) · Circulation
Heart Failure Treatment and ManagementHeart rate and cardiovascular health
Cited by 224
- Verified
The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 222
- Verified
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C.-E., Tereshchenko, S., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., et al. (2020) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 210
- Verified
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet
Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics
Cited by 209
- Verified · note
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
Kristensen, S. L., Mogensen, U. M., Jhund, P. S., Petrie, M. C., Preiss, D., Win, S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., et al. (2017) · Circulation
Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management
Cited by 202
- Verified
Effects of dapagliflozin in stage 4 chronic kidney disease
Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology
Chronic Kidney Disease and DiabetesDiabetes Treatment and Management
Cited by 201
- Verified
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation
Heart Failure Treatment and ManagementHeart rate and cardiovascular health
Cited by 186
- Verified
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA
Pancreatitis Pathology and TreatmentLipoproteins and Cardiovascular Health
Cited by 181
- Verified
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 175
- Verified
Incidence and Predictors of Hyperkalemia in Patients With Heart Failure
Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology
Potassium and Related DisordersHeart Failure Treatment and Management
Cited by 170
- Verified · note
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
McMurray, J. J. V., Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D., & Krum, H. (2018) · JACC: Heart Failure
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 165
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free